Pre-transfusion testing for patients receiving the Daratumumab
Keywords:
-Abstract
-
Downloads
Download data is not yet available.
References
เอกสารอ้างอิง
1. DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. Available from https://www.darzalex.com/what-is-multiple-myeloma, 2017.
2. DARZALEX® (daratumumab) injection: PATIENT INFORMATION DARZALEX® (Dar’-zah-lex) (daratumumab) injection, for intravenous use: Janssen Biotech,
Inc; 2015.
3. Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J. 1996;10:1408-17.
4. Chapuy CI, Aguad MD, Nicholson RT, AuBuchon JP, Cohn CS, Delaney M, et al. International validation of a dithiothreitol (DTT)-based method to resolve the
daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964-72.
5. Sullivan HC, Gerner-Smidt C, Nooka AK, Arthur CM, Thompson L, Mener A, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood.
2017;129:3033-37. doi. 10.1182/blood-2016-11-749432. Epub 2017 Apr 13.
6. Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, et al. Consideration for pre-transfusion immunohaematology testing in patients
receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Intern Med. 2018;48:210-20.
7. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing.
Transfusion. 2015;55:1545-54.
8. De Vooght KM, Osstendorp M, van Solinge WW. Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing. Transfusion. 2016;56:778-9. Australian and New Zealand Society of Blood Transfusion. Guideline for transfusion and immunohaematology laboratory practice. Sydney: The Australian &
New Zealand Society of Blood Transfusion Ltd; 2016.
1. DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. Available from https://www.darzalex.com/what-is-multiple-myeloma, 2017.
2. DARZALEX® (daratumumab) injection: PATIENT INFORMATION DARZALEX® (Dar’-zah-lex) (daratumumab) injection, for intravenous use: Janssen Biotech,
Inc; 2015.
3. Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J. 1996;10:1408-17.
4. Chapuy CI, Aguad MD, Nicholson RT, AuBuchon JP, Cohn CS, Delaney M, et al. International validation of a dithiothreitol (DTT)-based method to resolve the
daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964-72.
5. Sullivan HC, Gerner-Smidt C, Nooka AK, Arthur CM, Thompson L, Mener A, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood.
2017;129:3033-37. doi. 10.1182/blood-2016-11-749432. Epub 2017 Apr 13.
6. Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, et al. Consideration for pre-transfusion immunohaematology testing in patients
receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Intern Med. 2018;48:210-20.
7. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing.
Transfusion. 2015;55:1545-54.
8. De Vooght KM, Osstendorp M, van Solinge WW. Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing. Transfusion. 2016;56:778-9. Australian and New Zealand Society of Blood Transfusion. Guideline for transfusion and immunohaematology laboratory practice. Sydney: The Australian &
New Zealand Society of Blood Transfusion Ltd; 2016.
Downloads
Published
2018-12-13
Issue
Section
บทความพิเศษ (Special article)
